Chinese Study: Carbocisteine Prevents COPD Exacerbations
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Chinese Study: Carbocisteine Prevents COPD Exacerbations

NEW YORK -- June 16, 2008 -- A study in Chinese patients with chronic obstructive pulmonary disease (COPD) indicates that the mucolytic agent carbocisteine can help slow the worsening of COPD symptoms in patients and, therefore, should be recognised as a worthwhile treatment. The study findings are available in the June 14 issue of The Lancet.

Nan-Shang Zhong, MD, Guangzhou Institute of Respiratory Disease, Guangzhou, China, and colleagues conducted a randomised, double-blind, placebo-controlled trial -- Preventive Effects on Acute Exacerbations of COPD With Carbocisteine (PEACE) study -- to assess whether carbocisteine could reduce the yearly exacerbation rate in patients with COPD.

The study evaluated 709 patients (aged 40-80 years) with COPD from 22 centres in China. All patients had a history of at least 2 COPD exacerbations in the previous 2 years, and all had remained clinically stable in the 4 weeks before the study.

Patients were randomised to receive either carbocisteine 1,500 mg QD (n = 354) or placebo (n = 355) for 1 year. The number of exacerbations declined significantly in the carbocisteine group compared with the placebo group (1.01 [standard error (SE) 0.06] vs 1.35 [SE 0.06]). This represented a significant 25% reduction in risk for the carbocisteine group (risk ratio 0.75; 95% confidence interval, 0.62-0.92; P = .004).

"Mucolytics, such as carbocisteine, should be recognised as a worthwhile treatment for prevention of exacerbations in Chinese patients with COPD," the authors concluded. They added that this inexpensive treatment could be vital for treating COPD in developing countries.

In an accompanying comment, Paul Albert, MD, and Professor Peter Calverley, University of Liverpool, Liverpool, United Kingdom, examined whether these findings can be applied to patients who are not of Chinese origin. "What is clear from PEACE is the rigorous clinical trials of existing drugs can offer new insights into COPD care," they said.

SOURCE: The Lancet

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities